chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tenderness at injection site lasting ~36 hours Noted weakness and loss in dexterity in hand Feeling of swelling in hand Pins and needles sensation in full arm and extending through fingers
Dizzy; All my body was itchy; Rash all over my body; A lot of cough; migraine; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizzy), PRURITUS (All my body was itchy), COUGH (A lot of cough), MIGRAINE (migraine) and RASH (Rash all over my body) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 062E21A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy and Iodine allergy. Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) for an unknown indication.    On 12-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Sep-2021, the patient experienced DIZZINESS (Dizzy), PRURITUS (All my body was itchy) and RASH (Rash all over my body). In September 2021, the patient experienced COUGH (A lot of cough) and MIGRAINE (migraine). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and DEXAMETHASONE (DECADRON [DEXAMETHASONE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, DIZZINESS (Dizzy), PRURITUS (All my body was itchy), COUGH (A lot of cough), MIGRAINE (migraine) and RASH (Rash all over my body) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
COVID 19; suspected COVID 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 41-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 29Sep2021 at 12:00 as dose 3 (booster), single (Lot number: FF2588) at the age of 40 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose Number: 2), for COVID-19 immunization; Bnt162b2 (Dose Number: 1), for Covid-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), outcome "unknown", described as "COVID 19"; SUSPECTED COVID-19 (medically significant), outcome "unknown", described as "suspected COVID 19". No follow-up attempts are possible. No further information is expected.
Pt presented with complaint of worsening shortness of breath.  He reports that he tested positive for COVID-19 on the 8th of December.  He has been doing well until the past few days.    He has noticed that over the past few days his oxygen levels dropped into the mid 80s with activity, and at rest.  At that time he decided come in for further evaluation.  In triage patient was hypoxic and placed on nasal cannula oxygen. He was given decadron an d IV fluids. Tachycardia improved after fluids given. EKG stable. CBC elevated however Covid markers are trending down. Patient is stable for discharge home. He was prescribed Tussinex  10-8 MG/5ML ,ascorbic acid 250 MG tablet, Dexamethasone 6 MG tablet, vitamin D3 25 MCG (1000 UT) tablet, zinc sulfate 220 MG capsule, ProAir HFA 108 (90 BASE) MCG/ACT HFA inhaler., benzonatate 100 MG capsule, 4 L nasal cannula.
headache; feeling tired; first dose 7/30/2020 and her second dose on 9/24/2020; feeling of melancholy was described as a feeling of rejection / escalated following both injections.; stomach issues / as a feeling of / being hungover / though she didn't drink alcohol; stomach issues / described as a feeling of motion sickness; loose stool; feeling of rejection; This case was reported by a consumer via call center representative and described the occurrence of headache in a 60-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included shingrix with an associated reaction of headache (1st dose received on 30th July 2020, experienced adverse events-blood in stool, tiredness, feeling blue, hangover effect, motion sickness, loose stools and feelings of worthlessness. refer link case- US2020AMR194807).   On 24th September 2020, the patient received the 2nd dose of Shingrix (intramuscular). In September 2020, less than a week after receiving Shingrix, the patient experienced feeling sad, hangover effect, motion sickness, loose stools and feelings of worthlessness. On 24th September 2020, the patient experienced drug dose administration interval too short. On 25th September 2020, the patient experienced headache and tiredness. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the headache, tiredness, feelings of worthlessness and drug dose administration interval too short were unknown and the outcome of the feeling sad was recovering/resolving and the outcome of the hangover effect, motion sickness and loose stools were recovered/resolved.   It was unknown if the reporter considered the headache, tiredness, feeling sad, hangover effect, motion sickness, loose stools and feelings of worthlessness to be related to Shingrix.  Additional details were provided as follows:  The patient received shingrix in the left arm. The patient received 2nd dose delayed than the recommended schedule, which lead to shortening of vaccination schedule. The day after the vaccination, the patient experienced headache and feeling tired. In less than a week, the patient was feeling of melancholy it was described as a feeling of rejection.  She was supposed to see her physician for a physical and then was told she would not see her physician but would receive the vaccine by a nurse.  It left her feeling rejected and that feeling escalated following both injections (1st and 2nd). In less than a week, the patient had stomach issues were described as a feeling of motion sickness or being hungover even though she did not drink alcohol. The patient experienced loose stool. The stomach issues presented 2 to 3 days following vaccine. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR194807:same patient
Beginning approximately two days after my first vaccine shot, I have experienced joint pain and stiffness.  It is most prevalent in my left shoulder and the middle finger of my right hand.  I have not had pain in these places before.  I have also had pain and stiffness in my knees and lower back, and I have had problems in these places before.  The pain is not debilitating and is relieved with Advil and Tylenol.  I expected it to just resolve itself, but it has not.  I have communicated this to my health care provider, Dr. , by telemedicine.
30-40 minutes after receiving her Janssen Covid 19 vaccine she could not get out of the car and walk.  Her legs collapsed and her son had to help her out of the car and hold her up and walk her up the stairs to her bedroom. She was having recent issues with muscle tremors and her Neurologist ruled out ALS, MS and Parkinsons.  She also developed a metallic taste in her mouth.
Suddenly my big right toe started to swell up. I thought I had cancer, and I would need amputation. I went to the podiatrist, and he informed me that I had Gout. He prescribed colchicine and a cortisone shot in that toe. Then my rheumatologist prescribed allopurinol. When the problem in the toe subsided. I started having pain in the back of my foot.  Got an injection in February of this year. It did not help. My doctor told me he doesn't recommend injection because it can weaken the Achilles tendon. I have been dragging my foot since January. I am going to go back to my doctor to see if he can give me an injection.
throatiness to voice, fever & became non ambulatory & like in coma on 3rd day;
Flublok given to a patient that is not 18 years old. Patient had no adverse symptoms.
This spontaneous report was received from a Registered Nurse refers to approximately an year old male patient. No medical history and drug allergy was reported. On 26-JAN-2012, the patient was vaccinated with M-M-R II (dose, strength, route and lot number were not reported). Other suspect therapies included VARIVAX (Merck) (dose, strength, route and lot number were not reported) and SINGULAIR 4 mg, chewable tablet (strength, route and lot number were not reported). On an unknown date the patient developed unspecified allergies for which patient was prescribed SINGULAIR on an unspecified date. On an unspecified date in November 2014, the patient experienced cough and congestion. For which patient was treated with ZITHROMAX (manufacturer unspecified). The outcome of cough and congestion was reported as recovered/resolved. The outcome of unspecified allergies (hypersensitivity) was unknown. Action taken with SINGULAIR was unknown. Causality assessment was not provided. The patient subsequently experienced fever (pyrexia) and measles type rash (rash morbilliform) while on therapy with PROQUAD (Merck) (case# 1502USA010492). This is one of several reports receivd from the same reporter. Additional information has been requested.
Sharp left arm pain from fingertips to neck. Most significant pain in medial arm above elbow with radiating pain to pinky and ring finger to the shoulder and neck. Pain lasted 5+ days (pain worsened until day 3 and began to diminish on day 4). Also experienced body aches and tiredness on day after vaccine was administered.
fever of 101.9 1 hr p/APAP; pt screamed for 1-2 hrs; started 4 hrs p/vax; taken to ER; seen the next day w/ a huge local react covering entire upper leg; 14SEP93 wheezing 1-2 hrs p/vax; pt recovered;
Hive at injection site  2 weeks after vaccine. Soreness, itching, swelling at injection site.
Pt received "Hep A" vaccine (unknown if Havrix or Vaqta).  Developed severe fatigue with joint achiness following day.  5 days after receiving vaccine, pt developed intermittent tingling/numbness in bilateral hands with bilateral upper arm achiness with associated mild weakness.  Saw me (PCP) in office on 5/13 with ongoing (but nonprogressive) symptoms (although fatigue was improving).
Initial and follow up information has been received from a physician concerning a 45 year old female with hypothyroidism, asthma, dust and mold allergies and attention deficit disorder who on 08-MAR-2007 at 3:35pm was vaccinated SC into the left arm with a first 0.5 ml dose of Pneumovax 23 (lot # 655152/0889F).  Concomitant therapy included LEVOXYL, ADDERALL TABLETS), ADVAIR, NASAREL, WELLBUTRIN and SEROQUEL.  A few hours after vaccination, at 5:00 pm, the patient developed a "warm knot" at the injection site of her left forearm.  She also complained of terrible body aches, fever, nausea and diarrhea.  She recovered from body aches, fever, nausea and diarrhea on 12-MAR-2007.  Additional information is not expected.
arm rash, another bad rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (arm rash, another bad rash) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.  No Medical History information was reported.  On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced RASH (arm rash, another bad rash). At the time of the report, RASH (arm rash, another bad rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported.  No treatment information provided.   This case was linked to MOD-2021-067091 (Patient Link).   Reporter did not allow further contact
33M, patient denies PMH p/w uvula and L tonsil swelling (laying on top of tongue), soreness, and difficulty breathing since waking up the morning of 12/23/2020; sob now resolved; swelling unchanged; patient stated he got COVID vaccine 12/22/2020.  No other complaints.   Received diphenydramine, famotidine, epinephrine and dexamethasone.  Patient admitted to the ED on 01/24/2021 with similar reaction  after receiving second COVID-vaccine shot.
Patient was injected with the Janssen COVID-19 Vaccine EUA however it is outside of the age guidelines. Patient is 16 years old
headache; small rash around the vaccination area.; This is a spontaneous report from Pfizer-sponsored program. A contactable consumer reported for self. A female patient of an unknown age received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose via an unknown route on an unknown date in Mar2021 for Covid-19 immunization. Medical history and concomitant drug were not provided. Patient experienced a headache and small rash around the vaccination area.  Outcome of the events was unknown.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
resp distress w/inspiratory & exp wheeze;02 sat 93% beginning 9PM 19AUG97;
Around 24 hrs post vaccination, the pt developed swollen, hot, redness and erythema size of a baseball at left deltoid. Treated with warm soaks and Omniceff.
Rash, Hives, trouble breathing, uncontrollable scratching, bleeding, welts.
About 4 hours after immunization given child's, cheeks and lips became swollen (PO for Atarax 25mg QID) Child on Atarax 25mg for severe Eczema routinely. No resp distress noted. Child's lips remained swollen for several days.
Itching burning red eyes, sensitive to light and sound, headache same to next day. Red unraised different size blotches and rash second to third day. Tingly gnawing itchy feeling under skin including vaginal and peri-rectal area. Sores and sloughing of mouth mucosa and lips, day 4 - 9. NIGHTQUIL on day 1 - 7. BENADRYL day 3 - 7. CLARITIN and PEPCID day 6. DIFLUCAN, ATARAX, miconazole. Prednisone, K-LOR, pantoprazole from day 7 until presently.
This is a spontaneous report from a contactable consumer (patient herself). A 27-years-old female patient received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: EN6208, Expiry Date: unknown) on 21Mar2021 10:00 and second dose on 10Apr2021 both via unspecified route of administration in the left arm at single dose for COVID-19 immunization. The patient denied any medical history. She had no allergies. The patient's concomitant medication included celecoxib. On an unknown date in 2021, after receiving the vaccine, the patient had tingling in hands and feet, headache and pins and needle sensation all over the body, and rash and swelling in eyelids. No emergency room or physician office was involved. No COVID-19 prior vaccination, since the vaccination the patient hadn't been tested for COVID-19. There were no relevant test. The patient did not received treatment. The outcome of the events was not recovered. No follow-up attempts are needed. No further information is expected
Pt vaccinated with Rubella after 2nd child born 10 days later pain and inflamation of knees & wrists, lasting several days, progressed on to pinched nerves & loss of use. Test showing Carpal Tunnnel Synd.  See WORM for details.
PT WAS VACCINATED ON RT DELTOID AT APPROX. 2PM AND LATER THAT NIGHT FELT ITCHING IN VACCINATION SITE, NEXT DAY HAD RASH AND AS DAYS PROGRESSED FELT SHOULDER AND RIGHT NECK PAIN. RASH WAS VISIBLE AT PHARMACY VISIT OF 2/26/2016 AND WAS TO SEE HER MD ON 2/29/2016.
headache; Very sore arm at the injection site; Language:  Report about COVID vaccine: Yes Reporting type: AE Reporter type: Patient Patient occupation: None of the above  Dose received: More than 3 Most recent dose details: product=COVID 19, brand=Pfizer,  Brand unknown=False, Lot unknown=False,  Other vaccine same date details:other vaccine same date product=Pfizer, Other vaccine same date vaccine date=04Apr2022, Other vaccine same date  vaccine location=Left Arm  If other vaccine in four weeks: Yes Other medications in two weeks: No  If covid prior vaccination: No If covid tested post vaccination: No Known allergies: No Other medical history: NA  Start Date/Time: Pfizer 04Apr2022 10:00 AM Location of injection for vaccine received same date: Pfizer - Left Arm Location of injection for vaccine received within 4 weeks PRIOR: Tetanus  - Right Arm Reason why batch/lot is Unknown: Not available/provided to reporter at the time of report completion Facility where the most recent COVID-19 vaccine was administered: Doctor's office/urgent care List of any other medications the patient received within 2 weeks of vaccination:No  Reported Event: Continuing headache 30+ hours after vaccination.  Very sore arm at the injection site. Prior to vaccination, was the patient diagnosed with COVID-19?:No Since the vaccination, has the patient been tested for COVID-19?:No Device Date : 05Apr2022
p/vax pt exp varicella dew drop type erythematous maculopapular-a few are excoriated;MD noted 25-30 lesions mainly on trunk;pt remained afeb;
Developed shingles on my side at plexus; This case was reported by a consumer via (Shingrix GSK Chatbot) interactive digital media and described the occurrence of shingles in an adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, 2 weeks after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The patient self reported the case. The age group was not reported but was selected as an adult as per vaccine indication. The age at vaccination was not reported. The patient developed shingles on side at plexus.
Information has been received from a healthcare professional concerning a female patient who was vaccinated with a first dose of varicella virus vaccine live. Thirteen days after vaccination the patient experienced swelling on her nose and right side of face as well as chicken pox on the trunk of her body. The patient was seen in the clinic, but treatment was unknown. No product quality complaint involved. Additional information has been requested.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 65-year-old female patient (pregnant) received BNT162b2 (BNT162B2), on 22Sep2021 as dose 3 (booster), single (Lot number: FF2588) at the age of 65 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 02Feb2021 as dose 1, single (Lot number: 028L20A), in left leg, on 02Mar2021 as dose 2, single (Lot number: 002A21A), in right arm and on 30Mar2022 at 10:00 as dose 4 (booster), single (Lot number: 045521A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "Sulfa" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL, start date: 01Jan2020; HYDROCHLOROTHIAZIDE, start date: 01Jan2020; ADVAIR, start date: 04Apr2022. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Testing positive 14 days after starting Paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19. Therapeutic measures included Paxlovid 150mg/100mg, for the treatment of COVID-19.  No follow-up attempts are possible. No further information is expected.
Swelling; Redness; Hard lump; Itching; This case was reported by a consumer and described the occurrence of swelling in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On 3rd December 2020, the patient received the 2nd dose of Shingrix. In December 2020, less than a week after receiving Shingrix, the patient experienced swelling, erythema, induration and pruritus. On an unknown date, the outcome of the swelling, erythema, induration and pruritus were unknown.   It was unknown if the reporter considered the swelling, erythema, induration and pruritus to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication. On Thursday, the patient received the second dose of Shingrix. The patient had a reaction which were not with the first dose. The patient experienced swelling, redness, hard lump and itching.
Tingling/ numbness in left side of face; felt like tingling was spreading across face under eye for 15-20 minutes; felt acute pressure in left ear; jaw popped also on that side
Fever, aches, pains, nausea, headaches, fatigue, muscle pains
chills, shortness of breath, new onset a-fib, overall ache, extreme fatigue  Still in a-fib w/ shortness of breath
Case number PHEH2015US021907, is an initial spontaneous report received from a nurse on 26 Oct 2015. This report refers to a 53 year old male patient. Medical history and concomitant medication were not reported. The patient was vaccinated with FLUVIRIN (batch number: 1514701) intramuscularly at a dose of 0.5 ml on 16 Oct 2015. On the same day, shortly after administration patient experienced rash and hive localized around the injection site. Outcome of the events was reported as unknown. Evens were reported to be non-serious and causality of the events was not reported.
This spontaneous report as received from a physician assistant (P.A.) via a company representative refers to himself, who was a male patient around 50 years old. On an unknown date, the physician assistant was vaccinated subcutaneously with one dose of ZOSTAVAX (lot # not reported). After receiving the ZOSTAVAX injection, the physician assistant developed "a lot of localized reaction that radiated down to his arm." The physician assistant thought it was "cellulitis" because of the "red streaking down the arm". It was unspecified whether the physician assistant sought for medical attention. The adverse event improved and it took about a week before physician assistant recovered. This is one of several reports received from the same source. Additional information has been requested.
Exanthema - Information has been received from a health care professional concerning a 7 year old female patient who on 01 Jun 1997 was vaccinated with one dose of varicella virus vaccine live.  On 20 Apr 2000 the patient developed a varicella rash with about 40 to 50 lesions and no fever.  The patient sought medical attention.  No further information is available.
Patient given MENACTRA and FLUARIX in Right arm. Then HPV in left arm. Immediately after giving HPV patient began to sway to right and had a loss of color in her face. MA grabbed arm of patient and positioned her to a Supine position. Patient was not conscious for 4-5 seconds and then regained consciousness. Patient was given ice pack and water. Patient described "blacking out" and not knowing what happened. She still felt nausea after 10 minutes of lying done and sitting in exam room. Patient sat in exam room for 15 minutes until she felt better and her facial color returned. Provider examined spoke to patient and then patient was released.
Severe rash on belly and in diaper area (never had this previously), large lump in thigh where shot was administered, and banging head on mattress and against mother's chest.
Patient states she had "violent reaction" after both SHINGRIX doses (I did not hear about the first one until now), w/ onset of fever over 100, nausea, vomiting, dry heaves and diarrhea starting 10 hours after vaccine, with slight numbness in both hands and slight shortness of breath, lasting 5-6 hours, and next day low grade temp and headache. Now better.